Actualités sur Health

07.05.2015 – 08:02
Sumitomo Dainippon Pharma Co Ltd and Takeda Pharmaceutical Company Limited
Sumitomo Dainippon Pharma Co. Ltd. and Takeda Pharmaceutical Company Limited Announce Decision to Terminate Their Agreement for the Joint Development and Exclusive Commercialization of Latuda® (lurasidone) - an Atypical Antipsychotic Agent, in Europe
Osaka, Japan (ots/PRNewswire) - Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon Pharma") (Head Office: Osaka, Japan: President: Masayo Tada) and Takeda Pharmaceutical Company Limited ("Takeda") (Head Office: Osaka, Japan: President and CEO: Christophe Weber) today jointly announced that their license ...
plus
06.05.2015 – 10:55
ViiV Healthcare
ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy
London (ots/PRNewswire) - First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine ViiV Healthcare today announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay(R)) and rilpivirine (Edurant(R)[1]) as maintenance ...
plus
04.05.2015 – 17:59
Qiagen N.V.
QIAGEN Posts 2014 Annual Report on Its Website
Venlo, The Netherlands (ots/PRNewswire) - QIAGEN N.V. has posted its 2014 Annual Report on its website at http://www.qiagen.com/About-Us/Investors/Financial-Information/Financial-Reports QIAGEN's Annual Report on Form 20-F for the year ended December 31, 2014 has been filed with the U.S. Securities and Exchange Commission (SEC) on February 27, 2015, a copy of which can be found on the website of the SEC at ...
plus
30.04.2015 – 09:02
AAZ
Autotest VIH® (HIV Self-Test) has Received the CE 0459 Mark
Paris (ots/PRNewswire) - A revolution in HIV testing The French company AAZ has announced that it has received the CE mark for the first self-administered HIV blood test which will be manufactured in France under the name autotest VIH(R). (Photo: http://photos.prnewswire.com/prnh/20150430/742768-a ) (Photo: http://photos.prnewswire.com/prnh/20150430/742768-b ) autotest VIH(R) will be available in pharmacies and on ...
plus
27.04.2015 – 13:01
Resverlogix Corp.
Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement
Calgary, Alberta (ots/PRNewswire) - The deal structure involves CAD$50 million in equity investments, and future China sales milestones and licensing royalties that could represent in excess of US$400 million Resverlogix Corp. ("Resverlogix" or the "Company") today announced that it has entered into a Framework ...
plus
24.04.2015 – 13:56
Daiichi Sankyo Europe GmbH
Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Europe
Tokyo (ots/PRNewswire) - - The European Committee for Medicinal Products for Human Use recommended approval of once-daily Lixiana(R) - The positive opinion is based on data from the ENGAGE AF-TIMI 48 and Hokusai-VTE studies, the largest single comparative global trials of a novel oral anticoagulant in patients with ...
plus
24.04.2015 – 09:01
European Liver Patients Association (ELPA)
European Liver Patients Association (ELPA) Launches New Digital Guide for People Diagnosed with Hepatitis C
Brussels (ots/PRNewswire) - There are approximately nine million people in Europe infected with the hepatitis C virus, with tens of thousands of new cases diagnosed each year - and this trend is rising.[1] Currently there is no single online resource where people diagnosed with hepatitis C can go to find out more ...
plus
24.04.2015 – 09:00
Brainlab AG
Brainlab Introduces New Generation of VMAT* for Brain and Spine at 3rd ESTRO in Barcelona
Munich (ots) - Introduction of new "Elements" completes the portfolio of automated, indication-specific planning tools for radiosurgery/SBRT The "Elements" strategy-indication-specific focused software applications aimed at enhancing the workflow for difficult to treat indications in the brain and spine introduced in 2013-comes full circle with the introduction of ...
plus
23.04.2015 – 08:32
Debiopharm International SA
Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1450 in Staphylococcal Skin Infections
Lausanne, Switzerland (ots/PRNewswire) - One year after the initiation of Phase I, Debiopharm announced the start of clinical phase II for Debio 1450 in ABSSSI and presentation of new data at ECCMID Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical ...
plus
20.04.2015 – 14:02
Merck and Pfizer
Global Strategic Partners Merck and Pfizer Initiate Phase III Study with Avelumab* in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer
Darmstadt, Germany And New York (ots/PRNewswire) - Not intended for UK-based media - First of several registration trials expected to start in 2015 for the alliance between Merck and Pfizer - Initiation and first patient treated in Phase III clinical study recruiting across approximately 290 sites in more than 30 ...
plus
20.04.2015 – 09:02
Sanofi Pasteur MSD GmbH
Sanofi Pasteur MSD Welcomes the 10 year Anniversary
Lyon, France (ots/PRNewswire) - European vaccine leader hosts events across the region to help raise awareness of immunization throughout life Sanofi Pasteur MSD welcomes the World Health Organization's European Immunization Week 2015 (EIW 2015) with a series of awareness-raising events across the region, taking place between April 20th and 25th. Sanofi Pasteur MSD, a European leader for vaccines in Europe, has joined ...
plus
17.04.2015 – 16:32
AstraZeneca GmbH
"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC
Geneva (ots/PRNewswire) - ASSESS shows plasma circulating tumour DNA (ctDNA) testing for EGFR mutation is a viable alternative to tumour biopsy IGNITE supports value of EGFR mutation testing in all patients with advanced NSCLC AstraZeneca today presented results from two key studies showing the effectiveness of plasma circulating tumour DNA (ctDNA) testing for ...
plus
16.04.2015 – 14:02
Debiopharm International SA
Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm presents preclinical results for 2 anti-cancer targeted therapies Debio 1143 and Debio 1347 Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet ...
plus
15.04.2015 – 08:02
Daiichi Sankyo Europe GmbH
Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland
Tokyo (ots/PRNewswire) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that Swissmedic, the regulatory authority of Switzerland, has granted approval of Lixiana(R) (edoxaban), an oral, once-daily selective factor Xa inhibitor, for the prevention of stroke and systemic embolism (SE) in ...
plus
14.04.2015 – 09:03
Novo Nordisk
Novo Nordisk Extends Programme for Children With Diabetes in Developing Countries
Bagsværd, Denmark (ots/PRNewswire) - Today, Novo Nordisk announced a three-year extension of its Changing Diabetes(R) in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 ...
plus
13.04.2015 – 15:31
CGI Group Inc.
Alberta Health Extends Application Maintenance Services Contract With CGI
Edmonton, Alberta (ots/PRNewswire) - Stock Market Symbols GIB.A (TSX) GIB (NYSE) http://www.cgi.com/newsroom CGI is pleased to announce the renewal of its application maintenance services (AMS) contract with the Ministry of Health in Alberta (Alberta Health) for three years. The original contract was signed in 2011 for three and a half years, and the high quality work ...
plus
07.04.2015 – 14:02
Merck and Pfizer
Global Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI® (crizotinib)
Darmstadt, Germany And New York (ots/PRNewswire) - Not intended for UK-based media - In the second and third quarters of 2015, Merck and Pfizer will begin co-promoting XALKORI in the United States, Canada, Japan and five European Union countries (France, Germany, Italy, Spain and the United Kingdom) - In the United States and Canada, XALKORI will be co-promoted by EMD ...
plus
07.04.2015 – 13:31
Resverlogix Corp.
Resverlogix Receives Two Patents for RVX-208 in China
Calgary, Alberta (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announces that it has received two China patent approvals covering RVX-208. A composition of matter patent, China No. 2007 8 0052349.8 titled, "Compounds for the Prevention and Treatment of Cardiovascular Disease" was granted until February 2027. A manufacturing patent, China No. ZL 2009 8 0106586.7 titled, "Methods of Preparing ...
plus
07.04.2015 – 08:01
Shire Pharmaceuticals Group Plc
Shire Announces Clear Regulatory Path Forward for SHP465, an Investigational Treatment for Adults with ADHD
Lexington, Massachusetts (ots/PRNewswire) - - Potential Launch of SHP465 Anticipated in Second Half of 2017 - Exclusivity for Shire's Overall ADHD Product Portfolio Extends to 2029 Shire plc today announces that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a clear regulatory path ...
plus
06.04.2015 – 14:01
Shire Pharmaceuticals Group Plc
Shire Comments on USPTO Petitions Related to LIALDA and GATTEX
Lexington, Massachusetts (ots/PRNewswire) - Shire plc acknowledges the two petitions filed with the U.S. Patent and Trademark Office (USPTO) on April 2nd by Hayman Capital Management regarding LIALDA(R) (mesalamine) and GATTEX(R) (teduglutide [rDNA origin]). The patents listed in the FDA Orange Book for LIALDA and GATTEX protect the innovation and value Shire brings to patients who benefit from these important medicines. ...
plus
01.04.2015 – 22:18
Pivotal Therapeutics Inc
Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients That Includes VASCAZEN® and an Omega-3 Fatty Acid Diagnostic Assay
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that the United Stated Patent and Trademark Office (USPTO) has ...
plus
31.03.2015 – 14:02
Takeda Pharmaceuticals Europe Ltd
New Post-hoc Analyses Extend Understanding of the Efficacy and Safety of Lurasidone in the Treatment of Schizophrenia
Vienna (ots/PRNewswire) - FOR MEDICAL MEDIA Takeda Pharmaceuticals International GmbH ("Takeda") and Sunovion Pharmaceuticals Inc. ("Sunovion") today announced the results from three post-hoc analyses evaluating the efficacy and safety of Latuda(R) (lurasidone) in patients with schizophrenia at the 23rd European ...
plus
31.03.2015 – 07:31
Galderma
World's Leading Rosacea Experts Join Forces for First Global Rosacea Awareness Month to Help Drive Awareness and Extend Support for the 40 Million People Affected by Rosacea
Lausanne, Switzerland (ots/PRNewswire) - For non-US media - Global Rosacea Tweetathon set to bring the realities of living with rosacea under the spotlight #ChatRosacea Today the world's first Global Rosacea Coalition, supported by the National Rosacea Society and many leading rosacea experts, called for greater ...
plus
30.03.2015 – 14:54
Sunovion Pharmaceuticals Europe Ltd
Sunovion Pharmaceuticals Europe Ltd. to Present New Data on LATUDA® ? (lurasidone) at the 23rd European Congress of Psychiatry
Vienna (ots/PRNewswire) - Sunovion Pharmaceuticals Europe Ltd. will present 10 new research posters on LATUDA(R) (lurasidone), an atypical antipsychotic treatment for adults with schizophrenia, at the 23rd European Congress of Psychiatry (EPA). The meeting will be held 28-31 March 2015 in Vienna, Austria. "We are ...
plus
27.03.2015 – 14:03
Sanofi Pasteur MSD GmbH
GARDASIL® 9, New HPV Vaccine from Sanofi Pasteur MSD Granted Positive Opinion by European Committee for Medicinal Products for Human Use
Lyon, France (ots/PRNewswire) - European Committee for Medicinal Products for Human Use (CHMP) granted positive opinion for GARDASIL 9, the first 9-valent HPV vaccine Sanofi Pasteur MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted ...
plus
24.03.2015 – 12:26
Astellas Pharma Europe Limited
Astellas Announces New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress
London (ots/PRNewswire) - Astellas Pharma Europe Ltd. today announced new data from the Phase 2 TERRAIN trial of enzalutamide compared to bicalutamide in metastatic castration-resistant prostate cancer (CRPC), as well as an updated overall survival analysis from the placebo-controlled Phase 3 PREVAIL trial of ...
plus
19.03.2015 – 13:02
Astellas Pharma Europe Ltd. and Medivation, Inc.
New Enzalutamide Data to Be Presented in Late Breaking News Plenary Session at European Association of Urology Congress
Chertsey, England (ots/PRNewswire) - Astellas Pharma Europe Ltd. and Medivation, Inc. announced that two enzalutamide abstracts will be presented at the annual European Association of Urology (EAU) Congress on March 24, 2015 in Madrid, Spain. (Logo: http://photos.prnewswire.com/prnh/20140522/689211 ) (Logo: ...
plus
10.03.2015 – 10:04
DENTSPLY Implants
Treatment Solutions From DENTSPLY Implants for Improved Quality of Life
Cologne, Germany (ots/PRNewswire) - A prosthetic solution with the comfort of a fixed restoration; a patient-specific suprastructure on transgingival implants that eliminates the need for additional abutments; and an implant for sloped ridge situations for excellent esthetic results. (Logo: http://photos.prnewswire.com/prnh/20150310/732980-a ) (Logo: ...
plus
10.03.2015 – 10:02
DENTSPLY Implants
DENTSPLY Implants-Continuous Commitment to Innovation, Science and Clinical Research
Cologne, Germany (ots/PRNewswire) - DENTSPLY Implants remains strongly committed to innovation, science and clinical research. Parallel to expanding worldwide, DENTSPLY Implants has continued its dedication to innovation, science and clinical research. The company is now truly global and the commitment to the extensive clinical research program and innovative product ...
plus
05.03.2015 – 09:02
Sanofi Pasteur MSD GmbH
European Commission Grants "2+1 Immunization Schedule" for Hexyon® 6-in-1 Paediatric Vaccine
Lyon, France (ots/PRNewswire) - This decision opens the way to making Hexyon(R) available to more infantsin European countries Sanofi Pasteur MSD announced today that the European Commission has granted a new vaccination schedule of the 6-in-1 paediatric vaccine Hexyon(R) (DTaP-IPV-HB-Hib vaccine) for a "2+1" schedule of administration, in addition to other possible ...
plus

Précédent39404142434445464748Suivant